Pharma major Lupin targets $1 bn revenue from inorganic growth by FY18
Sohini Das | Ahmedabad Jan 19, 2016 10:01 AM IST
Looking to add $1 billion in revenues from inorganic growth to reach its target turnover of $5 billion by 2018, pharma giant Lupin, which is currently worth $2 billion, says it is open to late stage speciality assets.
Lupin s chief financial officer Ramesh Swaminathan told Business Standard that while $200-300 million per acquisition is a sweet spot for the company historically, it does not mean that the company won t look at bigger acquisitions.
We re looking at adding $1 billion in revenues from inorganic growth to reach our target of $5 billion by 2018, he added.
Lupin, he said, will continue to scout for meaningful acquisitions that will enable the company to build and consolidate its position as an emerging global specialty pharmaceutical powerhouse. Acquisitions will help it bolster our existing global brands business specifically in the US, acquiring technological capabilities, entering new markets where it has no presence, the company said.
As such, the company has been making strategic acquisitions of late. Among them are the Gavis buyout for $880 million in July last year that gave it access to a $63.8 billion market as well as a deep pipeline. Another was Nanomi, a Danish technology company in the injectables space in 2014.
The Gavis acquisition enhanced our scale in the US generic market and also broadened our pipeline in dermatology, controlled substance products and other high-value, niche generics, said Swaminathan. The acquisition gave us manufacturing capabilities in the US along with a highly skilled US based R
/* 728×90, создано 05.02.11 */
google_ad_slot = “6127977750”;
google_ad_width = 670;
google_ad_height = 90;